Company intelligence / Profile preview

Naxospharma

Cesate, Italy

Ownership: Private
Development stage: Other

Overview

Chemistry-driven R&D biotech focused on discovering novel small molecule drug candidates, particularly berberine derivatives with anticancer properties, for licensing out. Compounds like NAX035 show preclinical efficacy in reducing tumor growth via RNA binding and protein silencing.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Aromics (Applied Research Using Omic Sciences SL)Istituto Nazionale dei Tumori (Milano)Biofin Laboratories srlSolaris Biotechnology SRLBiCTINDENA

Beyond the preview

Go deeper on Naxospharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Naxospharma.

Explore the full profile